Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7457 USD | +0.03% | -3.39% | -63.45% |
Apr. 15 | Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform | CI |
Apr. 02 | Top Midday Decliners | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.45% | 78.59M | |
-2.86% | 87.37B | |
+4.08% | 41.01B | |
-25.35% | 28.08B | |
+54.31% | 24.72B | |
-4.52% | 17.47B | |
-42.09% | 11.69B | |
-17.77% | 11.6B | |
-12.10% | 11.56B | |
+1.05% | 8.44B |
- Stock Market
- Equities
- GRTS Stock
- News Gritstone bio, Inc.
- HC Wainwright Lowers Gritstone bio's Price Target to $12 From $15, Maintains Buy Rating